Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Prescription Drugs

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1659289

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1659289

Metabolic Disorder Therapeutics

PUBLISHED:
PAGES: 94 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Metabolic Disorder Therapeutics Market to Reach US$136.6 Billion by 2030

The global market for Metabolic Disorder Therapeutics estimated at US$91.6 Billion in the year 2024, is expected to reach US$136.6 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes Therapeutics, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of the analysis period. Growth in the Hypercholesterolemia Therapeutics segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$23.8 Billion While China is Forecast to Grow at 10.4% CAGR

The Metabolic Disorder Therapeutics market in the U.S. is estimated at US$23.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.8 Billion by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Metabolic Disorder Therapeutics Market - Key Trends and Drivers Summarized

How Are Metabolic Disorder Therapeutics Addressing Growing Health Concerns?

Metabolic disorder therapeutics are playing a critical role in addressing the rising prevalence of conditions such as diabetes, obesity, and hyperlipidemia, which are becoming major global health challenges. Metabolic disorders, characterized by disruptions in normal metabolic processes, often result in severe complications like cardiovascular diseases and stroke if left untreated. Therapeutics for metabolic disorders include a range of medications, lifestyle interventions, and, in some cases, surgical procedures. The growing burden of these disorders has led to increased research and development of novel drugs that target underlying metabolic pathways to manage and treat these conditions more effectively.

What Innovations Are Shaping the Metabolic Disorder Therapeutics Market?

Recent innovations in metabolic disorder therapeutics are focusing on personalized medicine and novel drug classes. Advances in genetic research have enabled the development of targeted therapies that can address the specific genetic and metabolic profiles of individual patients. For instance, GLP-1 receptor agonists and SGLT-2 inhibitors have emerged as breakthrough treatments for diabetes, offering improved blood glucose control and additional cardiovascular benefits. Additionally, gene therapies and biologics are being explored as potential treatments for rare metabolic disorders like Gaucher disease and Pompe disease, further expanding the therapeutic options available to healthcare providers.

How Do Market Segments Define the Growth of Metabolic Disorder Therapeutics?

Disorder types include diabetes, obesity, hyperlipidemia, and rare metabolic disorders, with diabetes therapeutics holding the largest market share due to the high global prevalence of the disease. Treatment types include medications, lifestyle interventions, and surgeries such as bariatric procedures, with medications leading the market due to their accessibility and effectiveness. Geographically, North America leads the market, driven by high healthcare expenditure and a growing diabetic population, followed by Europe and the Asia-Pacific region, where rising obesity rates are contributing to market growth.

What Factors Are Driving the Growth in the Metabolic Disorder Therapeutics Market?

The growth in the metabolic disorder therapeutics market is driven by several factors, including the increasing prevalence of lifestyle-related diseases, advancements in drug development, and growing awareness of metabolic health. Rising rates of obesity, diabetes, and cardiovascular diseases are creating a significant demand for effective therapeutic solutions. Technological advancements in drug discovery and personalized medicine are enabling the development of more effective and targeted treatments. Additionally, initiatives by governments and healthcare organizations to raise awareness about metabolic health and encourage early diagnosis and intervention are further driving market growth.

SCOPE OF STUDY:

The report analyzes the Metabolic Disorder Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity, Inherited Metabolic Disorders); Route of Administration (Oral, Parenteral, Other Route of Administrations)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biocon Ltd.
  • BioMarin Pharmaceutical, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla, Inc.
  • CymaBay Therapeutics, Inc.
  • Eli Lilly and Company
  • Merck KgaA
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Shire PLC
Show more
Product Code: MCP22257

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Metabolic Disorder Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Metabolic Disorders Drives Growth in Metabolic Disorder Therapeutics Market
    • Technological Advancements in Gene Therapy and Personalized Medicine Strengthen Business Case for Adoption
    • Growing Focus on Diabetes, Obesity, and Dyslipidemia Expands Addressable Market for Metabolic Disorder Therapeutics
    • Expansion of Biopharmaceuticals in Treating Metabolic Disorders Fuels Market Growth
    • Increasing Adoption of Combination Therapies and New Drug Formulations Expands Market Opportunities
    • Technological Innovations in RNA-Based Therapies and Targeted Treatment Propel Market Expansion
    • Growing Use of Metabolic Disorder Therapeutics in Precision Medicine Expands Market Potential
    • Rising Adoption of Injectable and Oral Therapies for Metabolic Disorders Expands Addressable Market
    • Technological Advancements in Insulin Delivery Systems and GLP-1 Receptor Agonists Propel Market Growth
    • Increasing Focus on Regulatory Compliance and Drug Safety in Metabolic Disorder Therapeutics Drives Adoption
    • Rising Demand for Non-Invasive and Long-Acting Treatments Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Metabolic Disorder Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metabolic Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Lysosomal Storage Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Inherited Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Inherited Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Inherited Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • JAPAN
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • CHINA
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • EUROPE
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Metabolic Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • FRANCE
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • GERMANY
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • INDIA
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Metabolic Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Metabolic Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030
  • AFRICA
    • Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!